Appendix Table 4.

Factors Associated With Detectable VL in Adjusted Models That Also Included Adherence and Substance Use Among Patients Receiving ART^*

Undetectable VL	OR	95% CI	P Value
Integrase strand transfer inhibitor use	0.81	0.73–0.90	<0.001
Female	1.14	0.95–1.37	0.167
Age (per decade, centered at 40 y)	0.77	0.72–0.82	<0.001
Race/ethnicity (reference is white race)
Black	1.97	1.69–2.31	<0.001
Hispanic	0.93	0.76–1.14	0.49
Other	1.02	0.74–1.40	0.92
Calendar time (year of cohort entry, centered around 2010)	0.90	0.87–0.93	<0.001
Years of follow-up	0.89	0.87–0.91	<0.001
Adherence	0.97	0.97–0.97	<0.001
Cocaine/crack use	1.16	0.99–1.36	0.069
Methamphetamine/crystal methamphetamine use	1.90	1.63–2.22	<0.001
Opiate/heroin use	1.25	0.96–1.61	0.093
Marijuana use	1.10	0.99–1.23	0.069
Hazardous alcohol use	0.90	0.81–1.01	0.070

ART = antiretroviral therapy; OR = odds ratio; VL = viral load.

^*Survival model component included in Appendix Table 8.